Published in J Virol on May 01, 1989
RGD sequence of foot-and-mouth disease virus is essential for infecting cells via the natural receptor but can be bypassed by an antibody-dependent enhancement pathway. Proc Natl Acad Sci U S A (1994) 2.49
The foot-and-mouth disease virus leader proteinase gene is not required for viral replication. J Virol (1995) 1.61
Identification of the active-site residues of the L proteinase of foot-and-mouth disease virus. J Virol (1995) 1.42
Antigenic heterogeneity of a foot-and-mouth disease virus serotype in the field is mediated by very limited sequence variation at several antigenic sites. J Virol (1994) 1.23
Receptor binding site-deleted foot-and-mouth disease (FMD) virus protects cattle from FMD. J Virol (1995) 1.23
Animal-derived antigenic variants of foot-and-mouth disease virus type A12 have low affinity for cells in culture. J Virol (1994) 1.21
DNA amplification-restricted transcription-translation: rapid analysis of rhesus rotavirus neutralization sites. Proc Natl Acad Sci U S A (1990) 1.20
Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants. J Virol (1991) 1.07
Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol (1991) 1.04
Vaccines prepared from chimeras of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies and protective immunity to multiple serotypes of FMDV. J Virol (1994) 1.02
Characterization of synthetic foot-and-mouth disease virus provirions separates acid-mediated disassembly from infectivity. J Virol (1997) 1.01
Propagation of an attenuated virus by design: engineering a novel receptor for a noninfectious foot-and-mouth disease virus. Proc Natl Acad Sci U S A (1996) 0.99
Sequence-based prediction for vaccine strain selection and identification of antigenic variability in foot-and-mouth disease virus. PLoS Comput Biol (2010) 0.98
Characterizing sequence variation in the VP1 capsid proteins of foot and mouth disease virus (serotype 0) with respect to virion structure. J Mol Evol (1998) 0.90
Evaluation and use of in-silico structure-based epitope prediction with foot-and-mouth disease virus. PLoS One (2013) 0.88
Genetic basis of antigenic variation in foot-and-mouth disease serotype A viruses from the Middle East. Vaccine (2013) 0.88
Evaluation of a genetically modified foot-and-mouth disease virus vaccine candidate generated by reverse genetics. BMC Vet Res (2012) 0.87
Antigenic stability of foot-and-mouth disease virus variants on serial passage in cell culture. J Virol (1991) 0.87
The Foot-and-Mouth Disease Carrier State Divergence in Cattle. J Virol (2016) 0.83
Pathogenesis of Primary Foot-and-Mouth Disease Virus Infection in the Nasopharynx of Vaccinated and Non-Vaccinated Cattle. PLoS One (2015) 0.83
Persistent Foot-and-Mouth Disease Virus Infection in the Nasopharynx of Cattle; Tissue-Specific Distribution and Local Cytokine Expression. PLoS One (2015) 0.83
Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins. J Virol (1998) 0.83
Early events in the pathogenesis of foot-and-mouth disease in pigs; identification of oropharyngeal tonsils as sites of primary and sustained viral replication. PLoS One (2014) 0.82
Genetic and antigenic characterisation of serotype A FMD viruses from East Africa to select new vaccine strains. Vaccine (2014) 0.81
Characterization of foot-and-mouth disease viruses (FMDVs) from Ugandan cattle outbreaks during 2012-2013: evidence for circulation of multiple serotypes. PLoS One (2015) 0.80
Prediction and characterization of novel epitopes of serotype A foot-and-mouth disease viruses circulating in East Africa using site-directed mutagenesis. J Gen Virol (2015) 0.79
Unprocessed foot-and-mouth disease virus capsid precursor displays discontinuous epitopes involved in viral neutralization. J Virol (1994) 0.79
Genetic heterogeneity in the leader and P1-coding regions of foot-and-mouth disease virus serotypes A and O in Africa. Arch Virol (2013) 0.77
Determining the epitope dominance on the capsid of a serotype SAT2 foot-and-mouth disease virus by mutational analyses. J Virol (2014) 0.77
Morphologic and phenotypic characteristics of myocarditis in two pigs infected by foot-and mouth disease virus strains of serotypes O or A. Acta Vet Scand (2014) 0.77
Laboratory animal models to study foot-and-mouth disease: a review with emphasis on natural and vaccine-induced immunity. J Gen Virol (2014) 0.76
Foot-and-mouth disease virus-neutralizing antibodies induced in mice by anti-idiotypic antibodies. Immunology (1989) 0.76
Pathogenesis of virulent and attenuated foot-and-mouth disease virus in cattle. Virol J (2017) 0.75
Emergence of antigenic variants within serotype A FMDV in the Middle East with antigenically critical amino acid substitutions. Vaccine (2016) 0.75
Cross-reactive idiotopes among anti-foot and mouth disease virus neutralizing antibodies. Immunology (1993) 0.75
Structure of a human common cold virus and functional relationship to other picornaviruses. Nature (1985) 12.90
Three-dimensional structure of poliovirus at 2.9 A resolution. Science (1985) 11.47
Structure-independent nucleotide sequence analysis. Proc Natl Acad Sci U S A (1979) 8.65
Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome. Nature (1985) 6.01
Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science (1981) 5.66
Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature (1982) 5.50
Myristylation of picornavirus capsid protein VP4 and its structural significance. Nature (1987) 5.26
Specific amino acid substitutions in bacterioopsin: Replacement of a restriction fragment in the structural gene by synthetic DNA fragments containing altered codons. Proc Natl Acad Sci U S A (1984) 3.67
Location and primary structure of a major antigenic site for poliovirus neutralization. Nature (1983) 3.64
Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. J Virol (1986) 3.59
Evidence for at least two dominant neutralization antigens on human rhinovirus 14. J Virol (1985) 3.44
Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology (1983) 3.04
Three-dimensional structure of poliovirus serotype 1 neutralizing determinants. J Virol (1988) 2.67
Nucleotide and amino acid sequence coding for polypeptides of foot-and-mouth disease virus type A12. J Virol (1985) 2.65
Location and characterization of the antigenic portion of the FMDV immunizing protein. J Gen Virol (1982) 2.62
Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science (1986) 2.62
Chemical basis of antigenic variation in foot-and-mouth disease virus. Nature (1984) 2.52
Critical role of an eight-amino acid sequence of VP1 in neutralization of poliovirus type 3. Nature (1983) 2.51
Antigenic variation and resistance to neutralization in poliovirus type 1. Science (1985) 2.19
Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site. J Virol (1986) 2.17
Rapid selection of genetic and antigenic variants of foot-and-mouth disease virus during persistence in cattle. J Virol (1988) 1.92
Coevolution of cells and viruses in a persistent infection of foot-and-mouth disease virus in cell culture. J Virol (1988) 1.90
Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus. J Immunol (1975) 1.76
Epitopes on foot-and-mouth disease virus outer capsid protein VP1 involved in neutralization and cell attachment. J Virol (1984) 1.75
Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3. J Gen Virol (1985) 1.72
Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res (1984) 1.71
Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J Gen Virol (1987) 1.53
Fixation of mutations in the viral genome during an outbreak of foot-and-mouth disease: heterogeneity and rate variations. Gene (1986) 1.53
Antigenic sites on foot-and-mouth disease virus type A10. J Virol (1988) 1.48
Early interactions of foot-and-mouth disease virus with cultured cells. Virology (1980) 1.45
Translation of foot-and-mouth disease virion RNA and processing of the primary cleavage products in a rabbit reticulocyte lysate. Virology (1982) 1.44
Analysis of neutralizing epitopes on foot-and-mouth disease virus. J Virol (1988) 1.32
Foot-and-mouth disease virus immunogenic capsid protein VPT: N-terminal sequences and immunogenic peptides obtained by CNBr and tryptic cleavages. Intervirology (1979) 1.26
Neutralization escape mutants define a dominant immunogenic neutralization site on hepatitis A virus. J Virol (1987) 1.22
Effect of lysosomotropic compounds on early events in foot-and-mouth disease virus replication. Virus Res (1987) 1.21
Recombinants between attenuated and virulent strains of poliovirus type 1: derivation and characterization of recombinants with centrally located crossover points. Virology (1985) 1.18
Genetic and immunogenic variations among closely related isolates of foot-and-mouth disease virus. Gene (1988) 1.12
Epitopes on foot-and-mouth disease virus particles. I. Topology. Virology (1987) 1.12
Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants. Virology (1988) 1.11
Prediction of three-dimensional models for foot-and-mouth disease virus and hepatitis A virus. Virology (1988) 1.11
Antigenicity and immunogenicity of synthetic peptides of foot-and-mouth disease virus. J Gen Virol (1987) 1.06
Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12. Virus Res (1984) 1.05
The adsorption and degradation of foot-and-mouth disease virus by isolated BHK-21 cell plasma membranes. Virology (1982) 1.04
Neurovirulence of the intertypic poliovirus recombinant v3/a1-25: characterization of strains isolated from the spinal cord of diseased monkeys and evaluation of the contribution of the 3' half of the genome. J Gen Virol (1985) 1.02
Foot-and-mouth disease virus: immunogenicity and structure of fragments derived from capsid protein VP and of virus containing cleaved VP. Vet Microbiol (1982) 1.01
Identification of an exposed region of the immunogenic capsid polypeptide VP1 on foot-and-mouth disease virus. J Virol (1983) 0.99
Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies. J Gen Virol (1986) 0.97
Evidence for a complex structure of neutralization antigenic site I of poliovirus type 1 Mahoney. J Virol (1988) 0.97
Surface structure and RNA-protein interactions of foot-and-mouth disease virus. J Gen Virol (1987) 0.96
Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells. J Virol (1985) 0.96
An epitope located at the C terminus of isolated VP1 of foot-and-mouth disease virus type O induces neutralizing activity but poor protection. J Gen Virol (1986) 0.96
Biochemical characterization of an aphthovirus type 0(1) strain campos attenuated for cattle by serial passages in chicken embryos. Virology (1985) 0.91
Epitope mapping of the outer structural protein VP1 of three different serotypes of foot-and-mouth disease virus. Virology (1986) 0.90
Antigenic comparison of foot-and-mouth disease virus serotypes with monoclonal antibodies. Virus Res (1986) 0.89
Biochemical characterization of an aphthovirus type C3 strain Resende attenuated for cattle by serial passages in chicken embryos. Virology (1987) 0.89
Modeling and computer stimulation approach to the mechanism of foot-and-mouth disease virus neutralization assays. Scand J Immunol (1977) 0.85
Crystallization and preliminary X-ray diffraction analysis of foot-and-mouth disease virus. J Mol Biol (1987) 0.84
Selection of coxsackievirus B4 variants with monoclonal antibodies results in attenuation. J Gen Virol (1987) 0.84
Comparison of the three-dimensional structure of two human rhinoviruses (HRV2 and HRV14). Proteins (1987) 0.80
STUDIES ON PNEUMONIA IN CHILDREN: I. Mortality, Blood Cultures, and Humoral Antibodies in Pneumococcus Pneumonia. J Clin Invest (1930) 11.23
A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature (2000) 10.16
Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose. Cell (1986) 8.87
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol (1995) 7.57
Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. Science (1992) 6.40
Cloned viral protein vaccine for foot-and-mouth disease: responses in cattle and swine. Science (1981) 5.66
Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (1993) 5.31
Crystal structure of cyclin-dependent kinase 2. Nature (1993) 5.21
Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. EMBO J (1992) 4.21
Inhibitory phosphorylation of the APC regulator Hct1 is controlled by the kinase Cdc28 and the phosphatase Cdc14. Curr Biol (1999) 3.96
Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (1998) 3.53
Insulin-like growth factor II receptor as a multifunctional binding protein. Nature (1987) 3.52
Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci U S A (1992) 3.38
A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase. Cell (1994) 3.35
A late mitotic regulatory network controlling cyclin destruction in Saccharomyces cerevisiae. Mol Biol Cell (1998) 3.18
Cdk-activating kinase complex is a component of human transcription factor TFIIH. Nature (1995) 3.05
The Polo-related kinase Cdc5 activates and is destroyed by the mitotic cyclin destruction machinery in S. cerevisiae. Curr Biol (1998) 2.92
Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis. J Virol (1996) 2.77
c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev (1995) 2.72
Activation of human cyclin-dependent kinases in vitro. Mol Biol Cell (1992) 2.68
Nucleotide and amino acid sequence coding for polypeptides of foot-and-mouth disease virus type A12. J Virol (1985) 2.65
The HIV transactivator TAT binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev (1997) 2.38
Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol (2000) 2.36
Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol (1999) 2.35
Nuclear localization of cyclin B1 controls mitotic entry after DNA damage. J Cell Biol (1998) 2.33
Association of p60c-src with endosomal membranes in mammalian fibroblasts. J Cell Biol (1992) 2.30
PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro. Proc Natl Acad Sci U S A (1994) 2.29
Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J Cell Biol (1996) 2.21
Pds1 and Esp1 control both anaphase and mitotic exit in normal cells and after DNA damage. Genes Dev (1999) 2.14
Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. EMBO J (1994) 2.08
Changing the needle when inoculating blood cultures. A no-benefit and high-risk procedure. JAMA (1990) 2.04
Cell cycle control by a complex of the cyclin HCS26 (PCL1) and the kinase PHO85. Science (1994) 1.94
Alternative mechanisms of CAK assembly require an assembly factor or an activating kinase. Cell (1995) 1.92
Insulin action is blocked by a monoclonal antibody that inhibits the insulin receptor kinase. Proc Natl Acad Sci U S A (1986) 1.80
Proteolytic processing of foot-and-mouth disease virus polyproteins expressed in a cell-free system from clone-derived transcripts. J Virol (1987) 1.77
Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus. J Immunol (1975) 1.76
Epitopes on foot-and-mouth disease virus outer capsid protein VP1 involved in neutralization and cell attachment. J Virol (1984) 1.75
Acute insulin action requires insulin receptor kinase activity: introduction of an inhibitory monoclonal antibody into mammalian cells blocks the rapid effects of insulin. Proc Natl Acad Sci U S A (1987) 1.73
Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase. Mol Cell Biol (1994) 1.71
A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK. Science (1996) 1.68
Distinct sub-populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J (1994) 1.67
Cdc37 is required for association of the protein kinase Cdc28 with G1 and mitotic cyclins. Proc Natl Acad Sci U S A (1995) 1.62
Synthesis of endogenous pyrogen by rabbit leukocytes. J Exp Med (1973) 1.58
Cdc14 activates cdc15 to promote mitotic exit in budding yeast. Curr Biol (2000) 1.58
Kaposi's sarcoma-associated herpesvirus K-bZIP protein is phosphorylated by cyclin-dependent kinases. J Virol (2001) 1.51
Identification of amino acid and nucleotide sequence of the foot-and-mouth disease virus RNA polymerase. Virology (1983) 1.51
Studies on the pathogenesis of fever. 18. Activation of leukocytes for pyrogen production. J Exp Med (1970) 1.49
Biochemical map of polypeptides specified by foot-and-mouth disease virus. J Virol (1984) 1.46
Suppression of c-Src activity by C-terminal Src kinase involves the c-Src SH2 and SH3 domains: analysis with Saccharomyces cerevisiae. Mol Cell Biol (1993) 1.44
Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. Mol Cell Biol (1995) 1.44
Changes in total light scattering and absorption caused by changes in particle conformation. J Theor Biol (1968) 1.40
Office-based system for voice analysis. Arch Otolaryngol Head Neck Surg (1989) 1.39
Cak1 is required for Kin28 phosphorylation and activation in vivo. Mol Cell Biol (1998) 1.39
Ran-independent nuclear import of cyclin B1-Cdc2 by importin beta. Proc Natl Acad Sci U S A (1999) 1.39
Multiple modes of ligand recognition: crystal structures of cyclin-dependent protein kinase 2 in complex with ATP and two inhibitors, olomoucine and isopentenyladenine. Proteins (1995) 1.35
Foot-and-mouth disease virus immunogenic capsid protein VPT: N-terminal sequences and immunogenic peptides obtained by CNBr and tryptic cleavages. Intervirology (1979) 1.26
Mechanisms of receptor-mediated transmembrane communication. Cold Spring Harb Symp Quant Biol (1986) 1.22
Transendothelial insulin transport is not saturable in vivo. No evidence for a receptor-mediated process. J Clin Invest (1996) 1.21
Synthesis of four endogenous pyrogens by rabbit macrophages. J Lab Clin Med (1979) 1.20
Sequence variation in the gene for the immunogenic capsid protein VP1 of foot-and-mouth disease virus type A. Proc Natl Acad Sci U S A (1985) 1.19
Competition for cellular receptor sites among selected aphthoviruses. Arch Virol (1982) 1.18
Laryngeal modeling: theoretical, in vitro, in vivo. Laryngoscope (1987) 1.13
Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants. Virology (1988) 1.11
A membrane-anchored cytoplasmic domain of the human insulin receptor mediates a constitutively elevated insulin-independent uptake of 2-deoxyglucose. Mol Endocrinol (1987) 1.11
Cdc37 promotes the stability of protein kinases Cdc28 and Cak1. Mol Cell Biol (2000) 1.11
Purification and crystallization of human cyclin-dependent kinase 2. J Mol Biol (1993) 1.10
Production of p60c-src by baculovirus expression and immunoaffinity purification. Methods Enzymol (1991) 1.09
Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop. Mol Cell Biol (2001) 1.09
Identification of neutralizing antigenic sites on VP1 and VP2 of type A5 foot-and-mouth disease virus, defined by neutralization-resistant variants. J Virol (1991) 1.07
Studies on the pathogenesis of fever. XVII. The cationic control of pyrogen release from exudate granulocytes in vitro. J Exp Med (1970) 1.07
Simultaneous isolation of Trichomonas vaginalis and collection of vaginal exudate. Br J Vener Dis (1969) 1.06
Evidence for at least four antigenic sites on type O foot-and-mouth disease virus involved in neutralization; identification by single and multiple site monoclonal antibody-resistant mutants. J Gen Virol (1989) 1.06
Location of neutralizing epitopes defined by monoclonal antibodies generated against the outer capsid polypeptide, VP1, of foot-and-mouth disease virus A12. Virus Res (1984) 1.05
Heterologous transmembrane signaling by a human insulin receptor-v-ros hybrid in Chinese hamster ovary cells. Proc Natl Acad Sci U S A (1987) 1.05
Mapping surface structures of the human insulin receptor with monoclonal antibodies: localization of main immunogenic regions to the receptor kinase domain. Biochemistry (1986) 1.04
Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol (1991) 1.04
Solitary eosinophilic granuloma of the lateral orbital wall. Am J Ophthalmol (1985) 1.03
Foot-and-mouth disease virus: immunogenicity and structure of fragments derived from capsid protein VP and of virus containing cleaved VP. Vet Microbiol (1982) 1.01
Dynamics of glucose production and uptake are more closely related to insulin in hindlimb lymph than in thoracic duct lymph. Diabetes (1994) 1.00
Protection of cattle and swine against foot-and-mouth disease, using biosynthetic peptide vaccines. Am J Vet Res (1990) 0.99
Peliosis hepatis in the acquired immunodeficiency syndrome. Arch Pathol Lab Med (1986) 0.99
Three-dimensional structure of human cyclin H, a positive regulator of the CDK-activating kinase. Nat Struct Biol (1996) 0.99
African swine fever virus multigene family 360 and 530 genes are novel macrophage host range determinants. J Virol (2001) 0.99
Identification of an exposed region of the immunogenic capsid polypeptide VP1 on foot-and-mouth disease virus. J Virol (1983) 0.99
Immunogenicity of namogram to milligram quantities of inactivated foot-and-mouth disease virus. I. Relative virus-neutralizing potency of guinea pig sera. Appl Microbiol (1969) 0.98
Plate binding assay for monoclonal anti-receptor antibodies. Endocrinology (1985) 0.98
Analysis of foot-and-mouth disease virus type O1 Brugge neutralization epitopes using monoclonal antibodies. J Gen Virol (1986) 0.97
Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells. J Virol (1985) 0.96
In vivo analysis of the stability and fitness of variants recovered from foot-and-mouth disease virus quasispecies. J Gen Virol (1998) 0.96
Videostroboscopy of the canine larynx: the effects of asymmetric laryngeal tension. Laryngoscope (1987) 0.96
The receptor for insulin-like growth factor II mediates an insulin-like response. EMBO J (1987) 0.96
Synovial sarcoma of the head and neck. Arch Otolaryngol Head Neck Surg (1987) 0.96